Zola-cel for autoimmune blood cell disorders
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new cell therapy designed to treat immune system problems that cause low blood cell counts in people with chronic immune thrombocytopenia (ITP) or autoimmune hemolytic anemia (AIHA). It may help when standard treatments have stopped working or caused bad side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with chronic ITP or AIHA (warm, cold, or mixed type).
- Your platelet count is very low (below 30) or, if you are on certain medicines, below 50. For AIHA, your hemoglobin is less than 10 or you need regular blood transfusions.
- Standard treatments such as steroids or other immune-suppressing medicines have not worked, stopped working, or caused unacceptable side effects. You have tried at least 2 different types of treatments for your condition.
- You do not have other active autoimmune diseases, certain infections (like HIV or hepatitis C), or a history of cancer within the last 2 years.
- Your blood test results must meet certain safety levels for white blood cells and liver function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (called CAR-T) for people with autoimmune hemolytic anemia or Evans syndrome that has not improved with standard treatments. The goal is to see if this therapy can control the condition and reduce the need for ongoing immune-suppressing drugs.
This trial tests a new type of immunotherapy called CAR T-cell therapy that targets two markers on your immune cells (CD19 and BCMA). It is for people with autoimmune hemolytic anemia (AIHA) who have already tried at least 3 standard treatments without success.
This study tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after other treatments. The goal is to see if this therapy can help control the disease and be safe.
This trial tests a combination of two medications—one that targets specific immune cells (CD20 antibody) and one that blocks a key enzyme in those cells (BTK inhibitor)—for people with ITP or AIHA that hasn't improved after standard treatments. The goal is to see if this combination can help control the disease and reduce symptoms.
This trial tests a new treatment using modified immune cells (CAR T-cells) to target and destroy the faulty cells that attack your blood cells in ITP or wAIHA. It aims to reset your immune system to stop the disease and improve blood counts.
This early-phase trial tests a new cell therapy (UCAR T cells) that targets specific markers on your immune cells (called CD19 and BCMA) to help stop your body from attacking your own red blood cells. It's for people with autoimmune hemolytic anemia that hasn't responded to multiple standard treatments.
Hear when a new Autoimmune Hemolytic Anemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.